Skip to main content

Design and results of a pilot community screening strategy for hepatitis B and hepatitis C to promote early access to treatment among migrant populations from high-prevalence countries residing in Catalonia (MiCatC)

In brief

Screening finds hepatitis B in 3% and HCV viremia in 1% of migrants

In a 10-month pilot across churches and community centres, 1,505 migrants (mostly Pakistani men) were tested, revealing hepatitis B surface antigen in 3% and active hepatitis C infection in 1%, all newly diagnosed. Multidisciplinary outreach linked most cases to hepatology and enabled treatment, but uptake was modest, highlighting the need for stronger gender-focused follow-up.

Journal
Journal of migration and health (Q1)
Published
14 July 2026
Study design
Unclassified
Evidence level
Level 5, Expert Opinion (CEBM 5)
Authors
Venus Forero, Sandra Manzanares-Laya, Hakima Ouaarab, Prat Jordi Gómez I, Anna Not, Marcos Montoro, et al.
PMID
42542640
DOI
10.1016/j.jmh.2026.100429

Why clinicians should know about it

Abstract

INTRODUCTION: The elimination of hepatitis C virus (HCV) and hepatitis B virus (HBV) requires strategies to overcome barriers associated with access to healthcare among migrants. The objective was to design and implement a community-screening-strategy (MiCat) for HBV and HCV among migrant populations from high-prevalence countries residing in Catalonia. METHODOLOGY: A pilot community-screening was conducted in religious sites, associations or community centres. A multidisciplinary team consisting of peer educators, community health agents, and nurses was established. interventions consisted of workshops pertaining to viral hepatitis, rapid tests featuring onsite results and the collection of dried blood samples for HCV RNA test if anti-HCV-positive result. HBsAg-positive and/or HCV-RNA-positive participants were contacted and referred for hepatology. RESULTS: A total of 1,505 people (71% men; 68% Pakistani) were screened over 10 months. Of the total, 71% were long-term residents in Catalonia (>5 years). The history of exposure was more common among women. A total of individuals tested, 3% (95% CI 2.2-4.0) (n=44) were HBsAg-positive (91% men; 33% new diagnoses), 36.4% (n=16) referred to hepatology (33% women) and 2 treated; and a 3.3% (95% CI 2.42-4.28) (n=49) were anti-HCV-positive (84% men), of these 32.6% (n=16) were HCV-RNA-positive (1.06% viremia prevalence; all new diagnoses), 13 patients completed the treatment. CONCLUSIONS: MiCatC project was able to detect, link to care and treat migrant population from countries with high prevalence of HCV and/or HBV based on a multidisciplinary team including community assets. It is essential to include the gender perspective to ensure that migrant women with hepatitis can receive specialised care.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.